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Insulin-dependent diabetes mellitus (IDDM) is a chronic disease characterized by T-cell-dependent autoimmune destruction of
the insulin-producing β cells in the pancreatic islets of Langerhans, resulting in an absolute lack of insulin. T cells are activated
in response to islet-dominant autoantigens, the result being the development of IDDM. Insulin is one of the islet autoantigens
responsible for the activation of T-lymphocyte functions, inﬂammatory cytokine production, and development of IDDM. The
aim of this study was to investigate serum concentrations of interleukin (IL)-1β, IL-2, IL-6, and tumor necrosis factor (TNF)-α in
children IDDM. The study population consisted of 27 children with IDDM and 25 healthy controls. Children with IDDM were
divided into three subgroups: (1) previously diagnosed patients (long standing IDDM) (n : 15), (2) newly diagnosed patients
with diabetic ketoacidosis (before treatment) (n : 12), and (3) newly diagnosed patients with diabetic ketoacidosis (after treatment
for two weeks) (n : 12). In all stages of diabetes higher levels of IL-1β and TNF-α and lower levels of IL-2 and IL-6 were detected.
Our data about elevated serum IL-1β,T N F - α and decreased IL-2, IL-6 levels in newly diagnosed IDDM patients in comparison
with longer standing cases supports an activation of systemic inﬂammatory process during early phases of IDDM which may be
indicative of an ongoingβ-cell destruction.Persistenceofsigniﬁcant diﬀerence between thecases with IDDMmonitored for a long
time and controls in terms of IL-1β,I L - 2 ,I L - 6 ,a n dT N F - α supports continuous activation during the late stages of diabetes.
Copyright © 2006 Yasar Dogan et al. This is an open access article distributed under the Creative Commons Attribution License,
which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
INTRODUCTION
Recent evidence favors primary role of cellular autoimmu-
nity and its humoral mediators in pathogenesis and follow-
ing IDDM [1]. IDDM is an autoimmune disease with an in-
ﬂammatory process directed against the β cells in pancreas
[2].Monocyteandtype1T-cell-derivedcytokinescontribute
to the pathogenesis of IDDM [3]. Chemokines play a central
role in inﬂammatory processes by regulating leukocyte mi-
gration into sites of tissue damage [4]. Cytokines have been
proposed as inducers of β-cell damage in human IDDM via
the generation of nitric oxide (NO) [5].
The autoantigen insulin is responsible for stimulation in
vitro of potentially hazardous memory lymphocytes to pro-
duce IL-6 and IL-10 [6]. A T helper 1 (TH1) subset of the
T cells and their cytokine products (type 1 cytokines: IL-
2, interferon (INF)-γ, and tumour necrosis factor (TNF)-
β) dominate over an immunoregulatory TH2s u b s e to fT
cells and their cytokine products (type 2 cytokines: IL-4,
IL-5, and IL-13). There is an imbalance between TH1a n d
TH2 subsets. This allows type 1 cytokines to initiate a cas-
cade of immune-inﬂammatory processes in the islet, which
includes activating macrophages to produce proinﬂamma-
tory cytokines. The proinﬂammatory cytokines, IL-1β,I L - 6 ,
and TNF-α, have cytotoxic, cytostatic (inhibits insulin syn-
thesis and secretion), or cytocidal actions to pancreatic islets
by inducing NO production [4, 6, 7].
Recent reports suggest that the pancreas participates in
TNF-α production during stress, and that the islets are pre-
dominantly responsible for such synthesis. IL-1β and TNF-
α are important for the β-cell lysis in IDDM, while IL-
1 receptor antagonist (IL-1ra) is considered protective by
blocking the eﬀects of IL-1 [2]. In vitro TNF-α and IL-1β
inhibit insulin release from islet β cells. It appears that the
process of autoimmune aggression against β cells, and its ef-
fect on insulin release and glucose homeostasis, is a slow and
chronic process. However, the production of these cytokines
and consequently the degree of β-cell destruction, in a genet-
ically susceptible subject, might be enhanced by several fac-
torsincludingviralinfections[8].Insomestudiesperformed
with newly diagnosed IDDM patients production of IL-1
was found to be increased signiﬁcantly when compared with
chronic IDDM patients and healthy controls. IL-1ra/IL-1
ratio decreased in patients with ND-IDDM and returned to2 Mediators of Inﬂammation
normal in LS-IDDM group. Circulating concentrations of
IL-1ra in LS-IDDM patients have increased. Any change in
TNF synthesis was not detected. This data suggests a proin-
ﬂammatory imbalance in ND-IDDM patients and this may
play an important role in β-cell loss [9].
The proinﬂammatory cytokines IL-1, IL-2, and TNF-α
may play important roles alone or in combination in the
pathogenesis of IDDM [10]. IL-1β and TNF-α levels can
be used as indicators of continuing autoimmune aggression
against β cells before the development of extensive β-cell de-
struction [8, 11]. Circulating IL-6, TNF-α, and CRP have
been also determined as markers of the inﬂammatory re-
sponse [12].
There is little and conﬂicting information regarding cir-
culating levels and in vitro production of cytokines in dia-
betes. Several studies have found an increase in serum IL-
6 concentrations [4, 13]; however some studies reported no
diﬀerence [14] or even decreased [15] IL-6 levels. Results re-
garding levels and/or production of TNF-α have been incon-
clusive and are reported to be increased [4, 16], decreased
[15],orunchanged[8,9]aswell.Theeﬀectsofglycemiccon-
trol on cytokines are consistent in several studies [4, 7], espe-
cially in children. The circulating levels of these cytokines in
the development of type 1 DM have no conclusion in diﬀer-
ent studies.
The aim of this study was to investigate serum con-
centrations of IL-1β,I L - 2 ,I L - 6 ,a n dT N F - α in children
IDDM.
MATERIALS AND METHODS
The study population consisted of 27 children with IDDM
and 25 healthy controls. Children with IDDM were divided
intothreesubgroups:(1)previouslydiagnosedpatients(long
standing IDDM) (n : 15), (2) newly diagnosed patients with
diabetic ketoacidosis (before treatment) (n : 12), and (3)
newly diagnosed patients with diabetic ketoacidosis (after
treatment) (n : 12).
After the written informed parental consents were ob-
tained, we collected the serum samples from 27 children
with IDDM (12 females, 15 males) at our pediatric dia-
betes clinics. Subjects with any diabetic complications such
as nephropathy, neuropathy or retinopathy, acute or chronic
diseases, or oral medication were excluded from this study.
All patients were treated with daily regular doses of insulin
(1IU/kg/d). Twenty ﬁve children without diabetes (11 fe-
males, 14 males) were recruited for the control group. The
age range of the subjects was 4–17 years. Baseline features of
the groups are presented in Table 1.
Thebackgroundinformationofsubjectssuchasage,gen-
der, body weight, body height, daily dose of insulin injec-
tion, and disease duration were recorded. Disease duration
was deﬁned in this study as the day of initial diagnosis of
diabetes to the day of blood collection. Blood samples (ﬁve
milliliters) were collected using standard venipuncture tech-
nique between 9:00 and 11:00AM. Serum samples were se-
pareted immedately after centrifugation at +4◦C, 4000rpm
f o r1 0m i n u t e sa n ds t o r e da t−20◦C until analysis.
Percent concentration of HbA1c in whole blood was
measured with Roche diagnostics HbA1c kits with auto-
analyzer (Cobas Integra 800 Autoanalyzer, Roche Diag-
nostics, Germany). This assay based on the immunotur-
bidometric determination of the stable glucose adducct to
N-terminal group of the haemaoglobin beta chain. Serum
concentrations of cytokines such as IL-1β,I L - 2 ,I L - 6 ,a n d
TNF-αweremeasuredusingcommerciallyavailableenzyme-
linked immunosorbent assay kits (ELISA kits, Biosource Int,
Calif).Alloftheserumsampleswereanalyzedinoneassayin
duplicate with intra- and interassay <10%. (IL-1β sensitivity
<2pg/mL, interassay %4.6, intrassay %3.4; IL-2 sensitivity
<0.1U/mL, interassay %7.5, intrassay %5.7; IL-6 sensitivity
<2pg/mL, interassay %8.0, intrassay %6.0; and TNF-α sen-
sitivity <3pg/mL, interassay %9.9, intrassay %5.2.)
STATISITICS
Data is presented as mean±SD. Comparison of variables was
performed with the general linear model, student t test, or
Mann-Whitney U test when necessary. Case-control diﬀer-
ences in nominal data were evaluated with the χ2 test. Statis-
tical analysis was performed using SPSS for Windows (SPSS
Advanced Statistics 7.5, SPSS, Chicago, Ill, 1997). The com-
parisons of serum cytokine between children with diabetes
andhealthyweredeterminedbymultivariateanalysisofvari-
ance (MANOVA). A simple linear correlation analysis was
processed by Pearson’s method to assess the correlation be-
tweenage,BMI,HbA1c,andcytokineinhealthyanddiabetic
subjects, respectively. A forward stepwise multiple linear re-
gression analysis was done to identify the inﬂuence of mul-
tiple variables, including age, diabetes, gender, BMI, HbA1c,
and cytokine in children with diabetes and healthy, respec-
tively. Statistical signiﬁcance was assumed at P<. 05.
RESULTS
In this study groups mean age and age range were as fol-
lows:controlgroup(10.5±1.0year)(8–13year),LS-IDDDM
group (10.6 ± 2.1 year) (7–15 year), and ND-IDDM group
(9.5 ± 1.6 year) (6–13 year). Mean diabetes duration was
2.9 ± 1.0 year in LS-IDDM groups. The present study was
c a rri e do u tt oi n v e s t i g a t es e ru mc o n c e n t ra t i o n so fb o d ym a s s
index (BMI), HbA1c, microalbuminuria, antistreptolysin O
(ASO), C-reactive protein (CRP), white blood cell (WBC),
and IL-6 and TNF-α in children with IDDM (Tables 1 and
2).
As shown in Table 1, the level of glucose were signif-
icantly higher in control groups compared to LS-IDDM
and ND-IDDM groups in this study (P<. 01,P<. 001).
Hba1c levels especially were signiﬁcantly higher than control
group compared to LS-IDDM and ND-IDDM groups. Also
there was a signiﬁcantly increase in the level of microalbu-
minuria in diabetic groups and the positive correlation was
showed between Hba1c level and microalbumin¨ uria in dia-
betic groups (r :0 .71, P<. 01 and r :0 .678, P<. 01).
In all stages of diabetes higher levels of IL-1β and TNF-α
and lower levels of IL-2 and IL-6 were detected. The resultsYasar Dogan et al 3
Table 1: Baseline characteristics of the study groups (mean ± SD).
Group 1 Group 2 Group 3
Control Long standing IDDM Newly diagnosed IDDM
(C) (LS-IDDM) (ND-IDDM)
Before treatment After treatment P-value
(BT) (AT)
n 25 15 12 12
Glucose (mg/dL) 84.8 ±13.8 158.3 ±21.7 470.9 ±98.1a,b 145.5 ±24.4
aP < .01 ND-IDDM versus C
ND-IDDM versus
LS-IDDM
bP < .01 LS-IDDM versus C
P<. 001 ND-IDDM
(BT versus AT)
HbA1c (%) 5.3 ±0.78 .0 ± 1.2b 9.9 ± 1.4a 8.6 ±1.1
aP < .01 ND-IDDM versus C
ND-IDDM versus
LS-IDDM
bP < .01 LS-IDDM versus C
P<. 05 ND-IDDM
(BT versus AT)
Microalbuminuria
(mg/L) 6.4 ±1.08 .1 ±1.5 10.2 ±3.8a 9.4 ± 2.9
aP < .001 ND-IDDM versus C
ND-IDDM versus
LS-IDDM
Urea (mg/dL) 21.8 ±4.2a 30.7 ±6.6b 38.1 ±10.6 31.4 ±11.8
aP < .01 C versus LS-IDDM
C versus ND-IDDM
bP < .05 ND-IDDM versus
LS-IDDM
P<. 05 ND-IDDM
(BT versus AT)
Creatinine (mg/dL) 0.5 ±0.10 .8 ±0.1 0.9 ±0.2a 0.8 ±0.2
aP < .01 ND-IDDM versus C
ND-IDDM versus
LS-IDDM
Creatinine clearance
(ml/dk) 80.5 ±10.6a 56.7 ±10.9 52.4 ±13.7 50.1 ±14.1 aP < .01 C versus LS-IDDM
C versus ND-IDDM
ASO (U/mL) 0.2 ±0.04a 1.5 ±0.3 2.0 ±0.5 1.3 ±0.4∗
aP < .01 C versus LS-IDDM
C versus ND-IDDM
P<. 05 ND-IDDM
(BT versus AT)
CRP (mg/L) 0.3 ±0.04 0.9 ±0.2 1.3 ±0.4a 0.9 ±0.3
aP < .05 ND-IDDM versus C
ND- IDDM versus
LS-IDDM
WBC (/mm3) 7745 ±1412 12126 ±3611a 9294 ±1647 8548 ±1593
aP < .05 LS-IDDM versus C
LS-IDDM versus
ND-IDDM
areshowninTables1and2.Therewasasigniﬁcantlypositive
correlation between the levels of IL-1β and IL-6 (r :0 .534,
P<. 05) and between the levels of IL-6 and TNF-α (r :0 .565,
P<. 05) in LS-IDDM. Also, in ND-IDDM group, a signiﬁ-
cantlypositivecorrelationbetweenthelevelsofIL-2andIL-6
(r : 0,698, P<. 01) and between the levels of IL-2 and IL-6
(r :0 .705, P<. 01) was showed.
DISCUSSION
Chemokines play a central role in inﬂammatory processes
by regulating leukocyte migration into sites of tissue dam-
age [4]. Cytokines have been proposed as inducers of β-
cell damage in human IDDM via the generation of NO
[5]. The proinﬂammatory cytokines IL-6 and TNF-α are4 Mediators of Inﬂammation
Table 2: Speciﬁc parameters of the study groups (mean ± SD).
Group 1 Group 2 Group 3
Control Long standing IDDM Newly diagnosed IDDM
(C) (LS-IDDM) ND-IDDM
Before treatment After treatment P-value
(BT) (AT)
n 25 15 12 12
IL-1β (pg/mL) 3.8 ±0.9a 12.2 ±2.1 13.7 ±2.3 10.7 ±2.0
aP < .01 C versus LS-IDDM
C versus ND-IDDM
P<. 05 ND-IDDM
(BT versus AT)
IL-2 (U/mL) 7.12 ± 2.03b 4.09 ±1.17 5.78 ±0.99a 5.01 ±1.93
aP < .01 LS-IDDM versus
ND-IDDM
bP < .001 C versus LS-IDDM
IL-6 (pg/mL) 3.08 ± 0.9a 14.7 ±3.1b 9.3 ±1.8 6.5 ±1.4
aP < .001 C versus LS-IDDM
C versus ND-IDDM
bP < .01 LS-IDDM versus
ND-IDDM
P<. 001 ND-IDDM
(BT versus AT)
TNF-α (pg/mL) 5.7 ±2.31 0 .8 ±13.3b 8.0 ±2.0a 6.3 ±1.5
aP < .05 ND-IDDM versus C
ND-IDDM versus
LS-IDDM
bP < .05 LS-IDDM versus C
P<. 05 ND-IDDM
(BT versus AT)
common to both TH s u b s e t si nh u m a n s[ 4, 10]. TNF-α and
IL-6-mediated damage to micro- and macrovascular tissues,
altered insulin secretion through direct or through stim-
ulation of free fatty acid production, and altered glucose
homeostasis are suggested [17, 18]. IL-6 and TNF-α are
adipocyte-secreted factors [16, 17, 19]. TNF-α injection in-
duces an increase in the concentration of plasma triglyceride
and very low density lipoproteins [4]. The proinﬂammatory
cytokine production is elevated in diabetes and in cases of
elevated lipids. Diabetes induced abnormalities in fatty acid
metabolism have the potential to inﬂuence macrophage cy-
tokine release inducing upregulation of proinﬂammatory cy-
tokines [20, 21]. The proinﬂammatory cytokines IL-1, IL-2,
and TNF-α may play important roles alone or in combi-
nation in the pathogenesis of IDDM [10]. Circulating IL-6,
TNF-α, and CRP have been also determined as markers of
the inﬂammatory response [12].
The IL-2 system which involves IL-2 production, IL-2 re-
ceptor expression, and response to IL-2 is associated with
autoimmune phenomena. Immunological abnormalities in-
cluding autoimmune phenomena are believed to contribute
to the pathogenesis of IDDM. In IDDM, IL-2 production
by CD4-positive T lymphocytes within the IL-2 system is
thought to be selectively defective [22]. Deﬁcient production
of IL-2 has been reported in IDDM, but its cause has not
been elucidated [23, 24]. T lymphocytes are implicated in
thepathogenesisofIDDM.IL-2—aTH1lymphocyte-derived
cytokine—is at present considered to play an important role
in the etiopathogenesis of IDDM. Activated T lymphocytes
expressing IL-2 receptors are found at increased levels in the
peripheral blood in the prediabetic period, at diagnosis and
forseveralmonthsaftertheonsetofthedisease,buttheirrole
in the pathogenesis of the disease is not known [25]. In pre-
vious studies with variable outcomes, IL-2 levels were found
to be increased, decreased [22, 26, 27], or unchanged in pa-
tients with IDDM. These diﬀerences can be a result of diﬀer-
ent metabolic status or/and a diﬀerent stage of the autoim-
mune process [28].
IL-2 receptors are released in the circulation in response
to antigenic or mitogenic stimulation of T lymphocytes. Ab-
normal serum IL-2 receptor levels have been found in young
children with IDDM and prediabetes. This phenomenon is
acquired close to disease onset and is unlikely to be an early
marker of IDDM [29]. Soluble IL-2 receptor (sIL-2R) levels
reﬂect mononuclear cell activation and are elevated in a va-
riety of autoimmune, neoplastic, and infectious conditions.
Several investigators have studied sIL-2R levels in patients
with IDDM, but results (low and elevated) have been con-
ﬂicting [30].
The present study suggests the involvement of IL-2 in the
pathogenesisofIDDM.InourstudyIL-2levelsdecreasedno-
tablyinallgroups.Especiallyinpatientsmonitoredforalong
time with a diagnosis of IDDM a signiﬁcant decrease in IL-
2 levels is a striking ﬁnding (Table 2). These results conﬁrmYasar Dogan et al 5
the presence of an imbalanced cellular immune response in
IDDM patients and demonstrate that the IL-2 deﬁciency is
alreadypresentatthediagnosis[27].ThedecreasedIL-2syn-
thesis is speciﬁc for IDDM, not explainable solely as a con-
sequence of poor metabolic control, and thus, might be in-
volved in the pathogenesis of the disease [31]. The low levels
of IL-2 might be explained by an abnormal consumption or
by the presence of increased sIL-2R levels or by a serum fac-
tor which interferes with IL-2 production [32]. These results
suggest that in recent onset IDDM, IL-2-receptor-positive
circulating T cells require an IL-2 supply [24].
IL-6 might play a signiﬁcant role in IDDM etiopatho-
genesis [32]. Diabetic patients have elevated blood levels of
IL-6, which is known to increase the inﬂammation and the
development of vascular disease and atherosclerosis [33]. IL-
6 levels were found to be decreased statistically signiﬁcantly
in any group of children with IDDM especially in newly di-
agnosed cases when compared with healthy controls. Even
a statistically signiﬁcant diﬀerence was revealed between IL-
6 values related to newly diagnosed cases and those found
during the posttreatment period (Table 2). In our study IL-6
levels did not reach to those of healthy children even though
they rised from their lowest values in newly diagnosed cases
to posttreatment values, and increased further in IDDM pa-
tients monitored for a long-term. However in some studies
IL-6 levels were found to be higher in newly diagnosed cases
when compared with those monitored for a long time [4].
The reports of IL-6 abnormal production in patients with
IDDM are rare [25].
TNF-α remained at its highest levels in all chronic cases.
Even a statistically signiﬁcant diﬀerence existed between
newly diagnosed cases and posttreatment group. Higher lev-
els of TNF-α found in every stage of the disease indicate the
persistence of activation of systemic immune inﬂammatory
response [4]. In our cases levels of TNF-α increased paral-
lel with the chronicity of the disease. However Erbagci et al
[4] found higher levels in newly diagnosed cases. In con-
trast with our ﬁndings, Netea et al [9] revealed that TNF-α
concentrations did not change in newly diagnosed cases and
chronic IDDM patients.
In this study serum ASO, CRP, WBC, and proinﬂamma-
tory cytokine concentrations (IL-1β, IL-6) indicated a state
of chronic inﬂammation in all patients with IDDM. Levels of
IL-1β and IL-6 in all DM groups were detected to be signif-
icantly diﬀerent from those of healthy controls. TNF-α lev-
els in all DM groups were found to be signiﬁcantly diﬀerent
from both control and all other groups including posttreat-
ment groups. However Erbagci et al [4] revealed that CRP,
IL-6, and TNF-α levels were not diﬀerent from those of con-
trol group.
Changes in interleukin levels are not limited to early
stages of the disease but it persist in advanced stages. In some
studies these changes were found to be restricted to only the
ﬁrst stage of the disease [31].
In this study we compared patients in diﬀerent stages
of diabetes among themselves and with healthy control
group. Our data about elevated serum IL-1β,T N F - α and de-
creased IL-2, IL-6 levels in newly diagnosed IDDM patients
incomparisonwithlongerstandingcasessupportsanactiva-
tion of systemic inﬂammatory process during early phases of
IDDM which may be indicative of an ongoing β-cell destruc-
tion. Persistence of signiﬁcant diﬀerence between the cases
with IDDM monitored for a long time and controls in terms
of IL-1β,I L - 2 ,I L - 6 ,a n dT N F - α supports continuous activa-
tion during the late stages of diabetes.
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